Navigation Links
Boston Scientific Announces Court Decision
Date:9/15/2008

intellectual property litigation and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
NIR is a trademark of Medinol, Ltd. '/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Vermillion, Inc. (Pink ... announced William C. Wallen, Ph.D. Chief Scientific ... for IDEXX Laboratories, will be joining its ... bankruptcy plan. ,, "Bill brings more ... in diagnostics and biotechnology," said Gail Page, ...
(Date:12/14/2009)... N.J., Dec. 14 The third edition ... , published by the Infusion ... treatment for anthracycline extravasation.(1) Anthracyclines are a ... and epirubicin that have been used in the ... early 1970s.(2) ,, According to the ...
(Date:12/14/2009)... -- Nektar Therapeutics (Nasdaq: NKTR ) announced ... serve on its board of directors. Winger ... 35 years of experience in corporate management, financial ... extensive industry perspective at an important time in ... and CEO of Nektar and member of the ...
(Date:12/14/2009)... - Results From a Survey Conducted by ... Major Industrialized Countries , , - A ... impacts their enjoyment of the ... arthritis find shopping for gifts, ... difficult to do, ...
Breaking Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4
... Clinical Environments - Without the High Costs of ... ... Upgrades, OAKLAND, Calif., Aug. 21 LUMEDX Corporation, a ... Cardiography Products, introduce CardioECG 3.2,multi-modality, multi-vendor, pure-Web software for cardiac ...
... NovaRx Corporation announced today,that the company initiated ... (belagenpumatucel-L) in the treatment of advanced non-small ... in the study was treated by,Dr. Lyudmila ... University,of California, San Diego School of Medicine., ...
... Netherlands, Aug. 21, Paul Capital Healthcare and ... today announced that they,have entered into a ... to fund SpePharm,s acquisition of Dantrium(R) for ... Gamble Pharmaceuticals. At the same,time, TVM Capital, ...
Other Biology Technology:LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution 2NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 2NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 3NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 4TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 2TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 3TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 4TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 5
(Date:12/15/2009)... toll on society. It is estimated that 100 to ... waters and it,s likely that rip currents account for more ... between rip current research and public understanding. Rip currents ... importantly, most people do not know how to even identify, ... of the Rip Current Symposium is to identify advancements in ...
(Date:12/14/2009)... (Dec. 14, 2009) -- Researchers at Rice University and ... nanoparticle that can be tracked in real time with ... them with a fluorescent dye and kills them with ... examples from a growing field called "theranostics" that develops ... in a single procedure. , The research is available ...
(Date:12/14/2009)... Engineering Society (BMES) have founded a new journal ... CVET is a forum for research on ... The first issue of the new quarterly journal will ... publications at Springer, Annals of Biomedical Engineering ... Cardiovascular Engineering and Technology will present a wide ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Biomedical Engineering Society's new journal to be published by Springer 2The Nations Mayors Commend New Healthcare Reform Legislation 51854 1The Nations Mayors Commend New Healthcare Reform Legislation 51854 2Regence Launches Effort to Further Health Care Debate 51852 1Regence Launches Effort to Further Health Care Debate 51852 2Regence Launches Effort to Further Health Care Debate 51852 3Governor Howard Dean to Appear at Barnes and Noble in Union Square 51849 1Governor Howard Dean to Appear at Barnes and Noble in Union Square 51849 2
... Technology Company,Limited, a global provider of fingerprint recognition software ... Mini Fingerprint,Scanner. , FS90 uses ... image,in a very small form factor. Its size is ... than one half of Futronic FS80 USB2.0 Fingerprint Scanner ...
... Since Congress lifted a moratorium on offshore drilling last year, ... to regulate U.S. ocean waters to allow oil, wave and ... animal habitats. , A new policy paper, ... of Duke University experts, argues that establishing a public trust ...
... The DNA in the 23 pairs of chromosomes in each of ... packed that it would measure six feet in length if stretched ... into a cell,s tiny nucleus because it is compressed into highly ... in the cell nucleus represents a massive condensation of the genetic ...
Other Biology News:Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner 2Public trust doctrine could aid management of US oceans 2Public trust doctrine could aid management of US oceans 3CSHL researchers explain process by which cells 'hide' potentially dangerous DNA segments 2CSHL researchers explain process by which cells 'hide' potentially dangerous DNA segments 3CSHL researchers explain process by which cells 'hide' potentially dangerous DNA segments 4
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
... denaturation and hybridization steps in slide-based (F)ISH ... and research personnel. The low cost unit ... is easy to use, and reduces hands-on ... overall precision and accuracy in all (F)ISH ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
Biology Products: